PROBLEM TO BE SOLVED: To provide immunotherapeutic compositions for the treatment of autoimmune diseases and disorders in human subjects.SOLUTION: The present invention relates to pharmaceutical compositions comprising monoclonal human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype in a pharmaceutically acceptable carrier. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC.COPYRIGHT: (C)2013,JPO&INPIT【課題】ヒト被験体における自己免疫疾患および自己免疫障害を処置するための免疫療法用の組成物の提供。【解決手段】IgG1またはIgG3ヒトアイソタイプのモノクローナルヒト抗CD19抗体、またはモノクローナルヒト化抗CD19抗体を薬学的に許容可能なキャリア中に含む、薬学的組成物。好ましくはヒトADCCを媒介する、IgG2またはIgG4ヒトアイソタイプのヒト抗CD19抗体またはヒト化抗CD19抗体を含む薬学的組成物。また、ヒトADCCを媒介する、IgG1、IgG2、IgG3またはIgG4アイソタイプのキメラ化抗CD19抗体を含む薬学的組成物。【選択図】図1-2
